$TXMD News

TherapeuticsMD Says Company Continues To Evaluate Strategic Alternatives, Including Acquisition Or Merger

TherapeuticsMD Q1 EPS $0.01 Up From $(0.06) YoY, Sales $724.000K Up From $393.000K YoY

TherapeuticsMD Q4 EPS $(0.06) Down From $0.01 YoY, Sales $893.000K Up From $667.000K YoY

TherapeuticsMD: Q3 Earnings Snapshot

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Q3 Sales $784.000K Up From $547.000K YoY

TherapeuticsMD Continues To Evaluate A Variety Of Strategic Alternatives

TherapeuticsMD Continues To Evaluate A Variety Of Strategic Alternatives

TherapeuticsMD: Q2 Earnings Snapshot

TherapeuticsMD Announces Second Quarter 2025 Financial Results

TherapeuticsMD Q2 EPS $0.05 Up From $(0.09) YoY, Sales $1.000M Up From $234.000K YoY

TherapeuticsMD: Q1 Earnings Snapshot

TherapeuticsMD Announces First Quarter 2025 Financial Results

TherapeuticsMD Q1 EPS $(0.06) Up From $(0.07) YoY, Sales $393.00K Up From $313.00K YoY

TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)

TherapeuticsMD Announces Full Year 2024 Financial Results

TherapeuticsMD FY24 EPS ($0.20) Up From ($0.74) YoY; Revenue $1.8M Up From $1.3M YoY

3 Promising US Penny Stocks With Over $9M Market Cap

TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD: Q3 Earnings Snapshot